Rumble Resources Limited (ASX:RTR) Updates on Western Queen Mine Development
Rumble Resources (ASX:RTR) reports progress on Western Queen Mine development and high-grade exploration, with first ore mining expected by year-end.
Tag: Industry-Specific News
Rimfire Pacific Mining (ASX:RIM) Continues Scandium Drilling Progress
Rimfire Pacific Mining (ASX:RIM) reports on its ongoing scandium drilling at Currajong, with assay results expected in late April.
PainChek Ltd (ASX:PCK) Secures $1.41M R&D Tax Refund, Advances FDA Review, and Launches Infant App
PainChek Ltd (ASX:PCK) secures a $1.41m R&D tax refund, advances FDA review for its Adult App, and launches the Infant App on Apple App Store.
Mercury (ASX:MCY) Forecasts 3,400 GWh Hydro Generation and Secures Long-term Contracts
Mercury (ASX:MCY) forecasts 3,400 GWh hydro generation for FY25 and enters long-term contracts with Fonterra and New Zealand Aluminium Smelters.
Green Critical Minerals (ASX:GCM) Advances VHD Graphite Commercialisation
Green Critical Minerals (ASX:GCM) advances its VHD Graphite technology with customer testing and first heat sink production, enhancing market validation.
Pro Medicus Limited (ASX:PME) Signs Multi-Year Research Collaboration with UCSF
Pro Medicus Limited (ASX:PME) enters a multi-year AI research collaboration with UCSF to advance healthcare imaging solutions.
Fenix Resources Limited (ASX:FEX) Announces Q1 2025 Quarterly Report and CZR Acquisition Offer
Fenix Resources (ASX:FEX) reports record Q1 2025 iron ore shipments and initiates takeover offer for CZR Resources.
Swift Networks Group Ltd (ASX:SW1) Secures $820,800 Subscription Deal with Newmont Mining
Swift Networks Group Ltd (ASX:SW1) secures a $820,800 subscription agreement with Newmont Mining for Swift Access at Tanami.
Aurumin Limited (ASX:AUN) Completes Gwendolyn Drilling Program
Aurumin Limited (ASX:AUN) completes RC drilling at Gwendolyn deposit, advancing near-term development with results expected mid-May.
Clarity Pharmaceuticals (ASX:CU6) Treats First Patient in Phase II SECuRE Trial
Clarity Pharmaceuticals (ASX:CU6) begins Phase II SECuRE trial with first patient treated and enhances 67Cu-SAR-bisPSMA formulation.